BioNTech (BNTX) vs Genmab A/S (GMAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Genmab A/S (GMAB) has outperformed BioNTech (BNTX) over the past year, gaining 12.3% versus a loss of 10.2%. Over five years, GMAB leads with a -17.5% price change compared with -61.5% for BNTX. BioNTech is the larger company by market cap ($23.16 billion vs $22.25 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | GMAB |
|---|---|---|
| Share price | $92.20 | $36.19 |
| Market cap | $23.16B | $22.25B |
| 1-day change | -3.20% | -1.26% |
| YTD return | +0.05% | +18.99% |
| 1-year return | -10.19% | +12.29% |
| 5-year return | -61.54% | -17.51% |
| P/E ratio (TTM) | — | 28.50 |
| Forward P/E | — | 23.73 |
| EPS (TTM) | $-7.83 | $1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.72B |
| Revenue growth (YoY) | — | +19.19% |
| Net income (latest FY) | — | $963.00M |
| Gross margin | — | 93.60% |
| Operating margin | — | 28.63% |
| Net margin | — | 25.89% |
| 52-week high | $124.00 | $40.17 |
| 52-week low | $79.52 | $23.62 |
| Distance from 52-week high | -25.65% | -9.91% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +25.59% | +19.43% |
| Average volume | 1.15M | 2.80M |
| Shares outstanding | 251.20M | 614.90M |
| Employees | 7,807 | 3,119 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GMAB has outperformed BNTX by 22.5 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
BNTX vs GMAB FAQ
Which is bigger, BioNTech or Genmab A/S?
BioNTech (BNTX) is larger, with a market capitalization of $23.16B compared with $22.25B for Genmab A/S (GMAB).
Which stock has performed better over the past year, BNTX or GMAB?
GMAB returned +12.29% over the past 12 months, compared with -10.19% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Genmab A/S in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioNTech and Biotechnology: Pharmaceutical Preparations for Genmab A/S.